Fortrea Holdings sits below the platform's quality floor with declining revenue and a failed momentum gate, though a cheap growth-adjusted valuation and short-interest-driven squeeze potential offer a partial offset.
Thesis pillars
- Quality Below Floor↓Deteriorating
- Declining Revenue Momentum Gate Failure→Stable
- Cheap Growth Adjusted Valuation→Stable
- +1 more pillar — see the Why tab for full reasoning
Fortrea Holdings Inc. (FTRE) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $19.92: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 12%; Elevated put/call ratio: 6.00; Below-average business quality.
Fortrea Holdings Inc. is a global contract research organization providing phase I-IV clinical trial management, clinical pharmacology, and consulting services to pharmaceutical, biotechnology, and medical device customers across more than 20 therapeutic areas. The company... Read more
Sell if holding. Engine safety override at $19.92: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 12%; Elevated put/call ratio: 6.00; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.2/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 4d<=7d. Suitability: speculative.
About Fortrea Holdings Inc.
About Fortrea Holdings Inc.
Fortrea Holdings' backlog stood at $7.7 billion as of December 31, 2025, built by a single Clinical Services segment spanning phase I through IV clinical trials, clinical pharmacology, and consulting for pharmaceutical, biotechnology, and medical device customers across more than 20 therapeutic areas. The company employs approximately 14,300 people across roughly 100 countries, and its top ten customers accounted for approximately 57% of 2025 revenue, with one customer alone contributing approximately 18.1%.
Fortrea earns revenue through three delivery models -- Full Service (integrated, project-centric), Functional Service Provider (staffing customers' internal programs), and Hybrid -- with Clinical Development, its largest offering for five consecutive years, covering regulatory affairs, patient recruitment, data management, and pharmacovigilance. Clinical Pharmacology operates four clinical research units in Leeds (U.K.), Dallas, Daytona Beach, and Madison, together offering roughly 376 beds for first-in-human and label-support studies. Oncology represented 40% of full-service therapeutic-based revenue in 2025, the company's largest single therapeutic concentration, built on more than 1,200 completed oncology trials over the prior five years. Fortrea also depends on strategic technology partners including Advarra, Cognizant, Medidata, and Veeva for the data and digital infrastructure underlying its trials, and remains subject to continuing contingent liabilities and indemnification obligations stemming from its 2023 spin-off from Labcorp.
Show full overview
Fortrea's customer base has grown more concentrated over time, not less: its top 20 customers rose from 61% of revenue in 2023 to 64% in 2024 and 69% in 2025, even as the company describes its base as large and diversified. That concentration compounds a structural contract risk -- once a project goes to contract, most customers can terminate without cause on 30 to 90 days' notice, and Fortrea's own backlog of $7.7 billion is explicitly not a reliable predictor of future revenue given the company's history of project delays, cancellations, and scope reductions.
See also: Healthcare · Biotechnology
From Fortrea Holdings Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-24Recent Developments — Fortrea Holdings Inc.
Latest news
- NEWS Mizuho Maintains Neutral on Fortrea Holdings, Raises Price Target to $16 — benzinga Jul 13, 2026 positive
Generated 2026-07-27T12:08:01Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWCustomerone customer18%10-K Item 1: 'As of the fiscal year ended 2025, one customer accounted for approximately 18.1% of our revenue'
- HIGHCustomertop ten customers57%10-K Item 1A: 'our top ten customers based on revenue accounted for approximately 57% of our consolidated revenue'
- HIGHCustomertop 20 customers69%10-K Item 1: 'Our top 20 customers represented approximately 69% of total revenue for 2025'
- MEDIUMProductoncology40%10-K Item 1: 'In 2025, 40% of our full service therapeutic-based revenue related to oncology studies'
Material Events(8-K, last 90d)
- 2026-06-26Item 5.02MEDIUMEffective July 6, 2026, Jason Knoblauch (previously EVP & CFO of Clario) will become Fortrea's CFO, succeeding Jill McConnell, who steps down as CFO on that date but will remain employed during a transition period.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Unprofitable operations — net margin -16.5%. Quality floor flags this regardless of sector context.static
Revenue shrinking — -2.3% YoY. Growth thesis broken unless recovery story develops.static
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $19.92: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 12%; Elevated put/call ratio: 6.00; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $18.15. Score 4.2/10, moderate confidence.
Take-profit target: $19.79 (-23.1% upside). Prior stop was $18.15. Stop-loss: $18.15.
Concentration risk — Customer: top ten customers (57.0%); Concentration risk — Customer: top 20 customers (69.0%); Target reached (-23.1% upside).
Fortrea Holdings Inc. trades at a P/E of N/A (forward 18.1). TrendMatrix value score: 6.0/10. Verdict: Sell.
17 analysts cover FTRE with a consensus score of 3.8/5. Average price target: $17.
What does Fortrea Holdings Inc. do?Fortrea Holdings Inc. is a global contract research organization providing phase I-IV clinical trial management,...
Fortrea Holdings Inc. is a global contract research organization providing phase I-IV clinical trial management, clinical pharmacology, and consulting services to pharmaceutical, biotechnology, and medical device customers across more than 20 therapeutic areas. The company employs approximately 14,300 people operating in about 100 countries, reports as a single Clinical Services segment, and had a backlog of $7.7 billion as of December 31, 2025; one customer accounted for approximately 18.1% of 2025 revenue, and its top ten customers represented approximately 57%.